• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌中双重/多重突变的流行病学:有证据表明一部分突变是由时间协调事件产生的。

Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.

作者信息

Chen Zhenbin, Feng Jinong, Buzin Carolyn H, Sommer Steve S

机构信息

Department of Molecular Genetics, City of Hope National Medical Center, Duarte, CA, USA.

出版信息

PLoS One. 2008;3(11):e3714. doi: 10.1371/journal.pone.0003714. Epub 2008 Nov 13.

DOI:10.1371/journal.pone.0003714
PMID:19005564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2579325/
Abstract

BACKGROUND

Evidence strongly suggests that spontaneous doublet mutations in normal mouse tissues generally arise from chronocoordinate events. These chronocoordinate mutations sometimes reflect "mutation showers", which are multiple chronocoordinate mutations spanning many kilobases. However, little is known about mutagenesis of doublet and multiplet mutations (domuplets) in human cancer. Lung cancer accounts for about 25% of all cancer deaths. Herein, we analyze the epidemiology of domuplets in the EGFR and TP53 genes in lung cancer. The EGFR gene is an oncogene in which doublets are generally driver plus driver mutations, while the TP53 gene is a tumor suppressor gene with a more typical situation in which doublets derive from a driver and passenger mutation.

METHODOLOGY/PRINCIPAL FINDINGS: EGFR mutations identified by sequencing were collected from 66 published papers and our updated EGFR mutation database (www.egfr.org). TP53 mutations were collected from IARC version 12 (www-p53.iarc.fr). For EGFR and TP53 doublets, no clearly significant differences in race, ethnicity, gender and smoking status were observed. Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse (6% and 2.3% versus 0.7%).

CONCLUSIONS/SIGNIFICANCE: Although no one characteristic is definitive, the aggregate properties of doublet and multiplet mutations in lung cancer are consistent with a subset derived from chronocoordinate events in the EGFR gene: i) the eight frameshift doublets (present in 0.5% of all patients with EGFR mutations) are clustered and produce a net in-frame change; ii) about 32% of doublets are very closely spaced (< or =30 nt); and iii) multiplets contain two or more closely spaced mutations. TP53 mutations in lung cancer are very closely spaced (< or =30 nt) in 33% of doublets, and multiplets generally contain two or more very closely spaced mutations. Work in model systems is necessary to confirm the significance of chronocoordinate events in lung and other cancers.

摘要

背景

有强有力的证据表明,正常小鼠组织中的自发双突变通常源于时间协调事件。这些时间协调突变有时反映“突变簇”,即跨越许多千碱基的多个时间协调突变。然而,对于人类癌症中双突变和多突变(多联体突变)的诱变情况知之甚少。肺癌约占所有癌症死亡人数的25%。在此,我们分析肺癌中表皮生长因子受体(EGFR)和肿瘤蛋白p53(TP53)基因多联体突变的流行病学情况。EGFR基因是一种癌基因,其中双突变通常是驱动突变加驱动突变,而TP53基因是一种肿瘤抑制基因,其更典型的情况是双突变源于一个驱动突变和一个乘客突变。

方法/主要发现:通过测序鉴定的EGFR突变从66篇已发表论文和我们更新的EGFR突变数据库(www.egfr.org)中收集。TP53突变从国际癌症研究机构(IARC)第12版(www-p53.iarc.fr)中收集。对于EGFR和TP53双突变,在种族、民族、性别和吸烟状况方面未观察到明显的显著差异。与小鼠中的自发双突变相比,人类肺癌中EGFR和TP53基因的双突变分别升高了约8倍和3倍(6%和2.3%对0.7%)。

结论/意义:尽管没有一个特征是决定性的,但肺癌中双突变和多突变的总体特性与源自EGFR基因时间协调事件的一个子集一致:i)八个移码双突变(存在于所有EGFR突变患者的0.5%中)聚集并产生净读框内变化;ii)约32%的双突变间隔非常紧密(≤30个核苷酸);iii)多突变包含两个或更多间隔紧密的突变。肺癌中的TP53突变在33%的双突变中间隔非常紧密(≤30个核苷酸),并且多突变通常包含两个或更多间隔非常紧密的突变。有必要在模型系统中开展工作以证实时间协调事件在肺癌和其他癌症中的重要性。

相似文献

1
Epidemiology of doublet/multiplet mutations in lung cancers: evidence that a subset arises by chronocoordinate events.肺癌中双重/多重突变的流行病学:有证据表明一部分突变是由时间协调事件产生的。
PLoS One. 2008;3(11):e3714. doi: 10.1371/journal.pone.0003714. Epub 2008 Nov 13.
2
Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency.自发多重突变既显示出与时间坐标事件一致的近端间距,也显示出p53缺陷导致的改变。
Mutat Res. 2004 Oct 4;554(1-2):223-40. doi: 10.1016/j.mrfmmm.2004.05.005.
3
EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.肺癌中的表皮生长因子受体(EGFR)体细胞双突变很常见,通常源于一对作为单突变不常见的驱动基因突变:三分之一的双突变发生在五对氨基酸处。
Oncogene. 2008 Jul 17;27(31):4336-43. doi: 10.1038/onc.2008.71. Epub 2008 Mar 31.
4
Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort.非小细胞肺癌中 TP53、KRAS 和 EGFR 突变的预后价值:EUELC 队列研究。
Eur Respir J. 2012 Jul;40(1):177-84. doi: 10.1183/09031936.00097311. Epub 2012 Jan 20.
5
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.非小细胞肺癌中表皮生长因子受体(EGFR)、人表皮生长因子受体2(HER2)、抑癌基因p53(TP53)及鼠类肉瘤滤过性毒菌致癌同源体基因(KRAS)突变模式与p14arf表达及吸烟史的关系
Cancer Res. 2007 Jun 15;67(12):5667-72. doi: 10.1158/0008-5472.CAN-06-4229.
6
Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.开发一种快速实用的人类肺腺癌突变筛选检测方法。
Int J Oncol. 2012 Jun;40(6):1900-6. doi: 10.3892/ijo.2012.1396. Epub 2012 Mar 7.
7
Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events.“大蓝”转基因小鼠近端多重突变是依赖事件的证据。
Mutat Res. 2000 Sep 18;452(2):219-29. doi: 10.1016/s0027-5107(00)00090-7.
8
Evidence for mutation showers.突变簇的证据。
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8403-8. doi: 10.1073/pnas.0610902104. Epub 2007 May 7.
9
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.肺癌中表皮生长因子受体基因的突变:生物学及临床意义
Cancer Res. 2004 Dec 15;64(24):8919-23. doi: 10.1158/0008-5472.CAN-04-2818.
10
Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.最大径线≤2cm 手术切除肺腺癌中 EGFR 和 p53 突变的临床病理特征及预后意义。
J Surg Oncol. 2014 Aug;110(2):99-106. doi: 10.1002/jso.23628. Epub 2014 Apr 30.

引用本文的文献

1
Crossing fitness valleys via double substitutions within codons.通过密码子内的双替换跨越适应度谷。
BMC Biol. 2019 Dec 16;17(1):105. doi: 10.1186/s12915-019-0727-4.
2
*K-means and cluster models for cancer signatures.用于癌症特征的K均值聚类模型
Biomol Detect Quantif. 2017 Aug 2;13:7-31. doi: 10.1016/j.bdq.2017.07.001. eCollection 2017 Sep.
3
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.具有罕见或复杂表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)患者的临床特征及治疗结果
Oncotarget. 2017 May 16;8(20):32626-32638. doi: 10.18632/oncotarget.15945.
4
Evolutionary switches between two serine codon sets are driven by selection.两种丝氨酸密码子集之间的进化转换是由选择驱动的。
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13109-13113. doi: 10.1073/pnas.1615832113. Epub 2016 Oct 31.
5
Clusters of Multiple Mutations: Incidence and Molecular Mechanisms.多重突变簇:发生率及分子机制
Annu Rev Genet. 2015;49:243-67. doi: 10.1146/annurev-genet-112414-054714.
6
Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2.FSHD2中的双SMCHD1变异:两个SMCHD1变异对FSHD2中D4Z4低甲基化和疾病外显率的协同作用。
Eur J Hum Genet. 2016 Jan;24(1):78-85. doi: 10.1038/ejhg.2015.55. Epub 2015 Mar 18.
7
Hypermutation in human cancer genomes: footprints and mechanisms.人类癌症基因组中的高突变:印记与机制
Nat Rev Cancer. 2014 Dec;14(12):786-800. doi: 10.1038/nrc3816.
8
Molecular mechanisms of disease-causing missense mutations.致病错义突变的分子机制。
J Mol Biol. 2013 Nov 1;425(21):3919-36. doi: 10.1016/j.jmb.2013.07.014. Epub 2013 Jul 16.
9
Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases.致癌潜能与受体酪氨酸激酶中致癌单、双体种系突变的激活效应有关。
Hum Mutat. 2012 Nov;33(11):1566-75. doi: 10.1002/humu.22145. Epub 2012 Jul 16.
10
Damage-induced localized hypermutability.损伤诱导的局部高突变性。
Cell Cycle. 2011 Apr 1;10(7):1073-85. doi: 10.4161/cc.10.7.15319.

本文引用的文献

1
EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.肺癌中的表皮生长因子受体(EGFR)体细胞双突变很常见,通常源于一对作为单突变不常见的驱动基因突变:三分之一的双突变发生在五对氨基酸处。
Oncogene. 2008 Jul 17;27(31):4336-43. doi: 10.1038/onc.2008.71. Epub 2008 Mar 31.
2
Too many mutants with multiple mutations.存在太多具有多重突变的突变体。
Crit Rev Biochem Mol Biol. 2007 Jul-Aug;42(4):247-58. doi: 10.1080/10409230701495631.
3
Evidence for mutation showers.突变簇的证据。
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8403-8. doi: 10.1073/pnas.0610902104. Epub 2007 May 7.
4
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.表皮生长因子受体(EGFR)体细胞突变数据库,分析显示存在插入缺失热点,但无吸烟相关特征。
Hum Mutat. 2007 Aug;28(8):760-70. doi: 10.1002/humu.20512.
5
The consensus coding sequences of human breast and colorectal cancers.人类乳腺癌和结直肠癌的共有编码序列。
Science. 2006 Oct 13;314(5797):268-74. doi: 10.1126/science.1133427. Epub 2006 Sep 7.
6
EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification.非小细胞肺癌中的表皮生长因子受体(EGFR)点突变偶尔会伴随第二种突变或扩增。
Cancer Sci. 2006 Aug;97(8):753-9. doi: 10.1111/j.1349-7006.2006.00233.x.
7
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.不同烟草暴露及临床病理特征的非小细胞肺癌患者中表皮生长因子受体和KRAS的独特突变模式
Clin Cancer Res. 2006 Mar 1;12(5):1647-53. doi: 10.1158/1078-0432.CCR-05-1981.
8
Clusters of mutations from transient hypermutability.来自瞬时超突变的突变簇
Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12849-54. doi: 10.1073/pnas.0503009102. Epub 2005 Aug 23.
9
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.肺腺癌对吉非替尼或厄洛替尼获得性耐药与表皮生长因子受体(EGFR)激酶结构域的二次突变有关。
PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22.
10
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.表皮生长因子受体(EGFR)突变与非小细胞肺癌对吉非替尼的耐药性
N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.